Mironid is a drug discovery company focused on therapeutics for degenerative kidney diseases, chronic inflammatory diseases, and cancer.
Mironid has raised $38.3M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
Mironid's investors include University of Strathclyde, Scottish Enterprise, Sofinnova Partners, BioGeneration Ventures, European Investment Fund.
Mironid is headquartered in Newhouse, United Kingdom.
Mironid is a drug discovery company focused on therapeutics for degenerative kidney diseases, chronic inflammatory diseases, and cancer.
Mironid is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mironid — Funding & Investors." VCBacked, September 13, 2023, https://www.vcbacked.co/company/mironid. Accessed July 31, 2026.
VCBacked. (2023). Mironid — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/mironid
{{cite web |title=Mironid — Funding & Investors |url=https://www.vcbacked.co/company/mironid |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated